Home / SAFE-PLASMA Protocol / Document

Notice of Intent to Sole Source

Updated

A Word document (16 KB) attached to SAFE-PLASMA Protocol, from the Defense Health Agency (DHA). Due Nov 23, 2026, 2:00 PM (UTC-5).

File name: B01-HT9427-27-NOI-701-Notice of Intent to Sole Source.docx

Download the full documentSee the bid

The full file is for paid members, or buy this bid alone.

Preview

Notice of Intent to Sole Source

The Defense Health Agency Contracting Activity (DHACA) on behalf of the Portfolio Acquisition Executive Medical Products (PAE MP), Warfighter Protection and Acute Care Project Management Office (WPAC PMO), intends to execute an modification to an existing award on a sole source basis under the authority of Revolutionary Federal Acquisition Regulation (FAR) Overhaul (RFO) 6.103-1, only one responsible source and no other supplies or services will satisfy agency requirements, to Westat Inc. 1600 Research Blvd. Rockville, MD 20850. This requirement will enable Westat Inc. to modify the current clinical trial design to comply with FDA recommendations and to conduct the Good Clinical Practices (GCP) compliant clinical trial in accordance with U.S. Food and Drug Administration’s requirements for EZPLAZ™ approval.

Westat Inc. is the only source able to meet the Government requirements. The purpose of this contract modification is to execute the performance of the GCP compliant clinical trial in accordance with FDA’s recommendations/requirements as part of EZPLAZ™ approval. Westat Inc. conducted the Phase 1 clinical trial used for EZPLAZ™ licensure and has developed the protocol and Statistical Analysis Plan for the current clinical trial evaluating the safety of EZPLAZ™ and conventional plasma products in adult patients.

This notice of intent is not a request for competitive proposals and no solicitation document exists for the requirement. Sources interested in responding to this notice are required to submit a capability statement that includes management and technical data and cost information, in sufficient detail and with convincing evidence that clearly demonstrates the capability to perform the required work. Capability statements shall not exceed five (5) pages (8.5 x 11 inch) using a font size no smaller than 10-point. All capability statements received by the due date of this notice will be considered by the Government. A request for documentation or additional information or submissions that only ask questions will not be considered as an affirmative response. A determination by the Government not to compete based on responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement or to proceed with a sole source contract modification.

Capability statements are due by 2:00 PM Local Time, 23 November 2026. Capability statements shall be submitted by e-mail ONLY as a Microsoft Word or Adobe PDF attachment to the following address: [email protected].

The beginning of the document. Download the full file to read on.